Publication & Citation Trends
Most Cited Works
Publications
50 total
Cemiplimab plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer with PD-L1≥1%: 5‑year update of EMPOWER-Lung 3 results
Cited by 0
Semantic Scholar
Efficacy and safety of avelumab + axitinib vs sunitinib in patients (pts) with very favorable-risk advanced renal cell carcinoma (aRCC): Subgroup analysis from the JAVELIN Renal 101 trial.
Cited by 0
Semantic Scholar
Abstract 653: Proved clinical benefit of low-dose anti-CTLA4 + anti-PD-1 immunotherapy versus mono anti-PD-1 therapy in patients unresectable or metastatic melanoma: Phase III OCTAVA trial
Cited by 0
Semantic Scholar
Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic (PD) markers and tumor gene expression by mevrometostat in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Cited by 0
Semantic Scholar
Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].
Cited by 0
Semantic Scholar
Results of phase III clinical trial of novel biosimilar of pembrolizumab (RPH-075).
Cited by 0
Semantic Scholar
Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.
Cited by 6
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(13)
Renal cell carcinoma treatment
(12)
Lung Cancer Research Studies
(12)
Lung Cancer Treatments and Mutations
(10)
Prostate Cancer Treatment and Research
(9)
Frequent Co-Authors
Affiliations
Russian Railways
Saint-Petersburg Medico-Social Institute
Institute of Oncology NN Petrov
City Clinical Hospital No 31
Euromedic